CTLA4 and hepatocellular carcinoma: Between 2017 and 2020, two human anti-PD-1 monoclonal antibodies (nivolumab and pembrolizumab) and an anti-CTLA4 monoclonal antibody (ipilimumab) were approved for advanced HCC, extending patients’ overall survival significantly [13,14,15].